Herein, we investigated the molecular mechanisms of the antitumor effects of CP in SCLC and demonstrated that combining CP with either MEK/ERK inhibitor U0126 or metformin could enhance the therapeutic effects of CP to target SCLC. The gene discussed is CP; the disease is small cell lung carcinoma.